Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
Continuous treatment with the anti-tumor necrosis factor alpha monoclonal antibody infliximab is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation results in disease relapse, with variable delay. Objective of this study was to compare efficacy between a continuous treatment with infliximab, and a treatment adapted to symptoms recurrence. Addition of methotrexate (MTX)to infliximab was also tested.
Epistemonikos ID: 966f87c562b344d87d849f5c89f8d01765da65b6
First added on: May 04, 2024